Myopia management is a set of treatments designed to slow the worsening of nearsightedness in children, not just correct it. Standard glasses fix blurry distance vision by bending light onto the retina, but they do nothing to stop the eye from continuing to grow longer. Myopia management targets that underlying growth, aiming to reduce the risk of serious eye problems later in life.
Why Correcting Vision Isn’t Enough
Nearsightedness happens when the eyeball grows too long from front to back. Light focuses in front of the retina instead of on it, making distant objects blurry. Regular glasses or contact lenses shift that focal point back onto the retina so a child can see clearly, but the eye keeps elongating year after year.
The retina appears to act as a growth regulator. When the image plane falls behind the retina, the eye receives a biological “go” signal and continues to lengthen. When it falls in front of the retina, a “stop” signal slows that growth. Standard single-vision lenses correct central focus but can leave peripheral light landing behind the retina, which may actually encourage further elongation. Myopia management treatments are engineered to manipulate where light lands across the entire retina, sending that stop signal more effectively.
Children who become nearsighted at a younger age tend to progress faster. One study tracking children transitioning into myopia found their eyes grew at roughly 1.08 millimeters per year after onset, compared to about 0.35 mm per year in kids who stayed non-myopic. That rate matters because every additional millimeter of eye length pushes the prescription higher and increases the chance of structural damage decades later.
Why Slowing Progression Matters Long-Term
Higher levels of myopia carry significantly greater risk of eye disease in adulthood. A long-term population study published in the British Journal of Ophthalmology found that the risk of developing open-angle glaucoma climbed steeply with increasing nearsightedness. Compared to people with normal or slightly farsighted eyes, those with low myopia had 3.2 times the risk, moderate myopia carried 4.2 times the risk, and high myopia (beyond negative 6 diopters) brought a 7.3-fold increase. The 10-year incidence of glaucoma reached 13.3% in the high myopia group versus just 2.1% in non-myopic eyes.
Glaucoma is only part of the picture. Longer eyes also face elevated rates of retinal detachment, myopic macular degeneration, and cataracts. These conditions can cause permanent vision loss. The goal of myopia management is to keep a child’s final prescription as low as possible, reducing cumulative risk over a lifetime.
Who Should Start and When
Proactive myopia management is now considered the standard of care by the International Myopia Institute, which in 2025 stated that stronger evidence and global consensus support early intervention to reduce long-term vision risks. The youngest patients with myopia deserve the most attention because the disease progresses fastest at younger ages.
Several factors flag a child as high priority: having one or two nearsighted parents, spending less than two hours a day outdoors, doing extended close-up work like reading or screens at short distances, and developing any degree of myopia early in elementary school. Delaying the onset of myopia by even one year provides a benefit comparable to two to three years of active treatment, so monitoring should begin well before a prescription appears. The American Optometric Association recommends a first comprehensive eye exam at six months of age, with ongoing checks to catch early shifts.
Low-Dose Atropine Eye Drops
Atropine is a medication traditionally used to dilate the pupil, but at very low concentrations it slows eye growth through a mechanism that researchers are still working to fully explain. The key finding across multiple large trials is that concentration matters in a somewhat counterintuitive way.
A concentration of 0.05% atropine reduced myopia progression by about 67%, while 0.025% achieved roughly 43% reduction. The lowest dose, 0.01%, still produced a meaningful slowing effect but was less potent than the higher concentrations. The five-year ATOM2 study initially suggested 0.01% was the sweet spot because higher doses caused more rebound growth after stopping. But the LAMP study, a more recent Phase 3 trial, found that rebound effects were clinically small across all concentrations, and that 0.05% remained the optimal choice overall. Stopping treatment at an older age and using a lower concentration both helped minimize any rebound.
Low-dose atropine drops are typically given once nightly. Side effects at these concentrations are mild, usually limited to slight light sensitivity or minor difficulty focusing up close, and far less bothersome than the older approach of using full-strength atropine.
Specialty Contact Lenses
Dual-focus soft contact lenses represent one of the most well-studied optical approaches. These lenses correct central vision normally while simultaneously projecting a slightly defocused image in the periphery, pushing that peripheral focal point in front of the retina to trigger the “stop growing” signal. In a three-year clinical trial, children wearing dual-focus lenses showed 59% less progression in their prescription and 52% less eye elongation compared to children in standard lenses.
One specific dual-focus daily disposable lens is the only FDA-approved contact lens for slowing myopia progression in children. It was approved for kids aged 8 to 12 at the start of treatment. Because these are daily disposables, hygiene and handling tend to be simpler than with reusable lenses, which matters for younger wearers.
Orthokeratology is another contact lens option. These rigid lenses are worn overnight to temporarily reshape the cornea, providing clear vision during the day without glasses. They also create a peripheral defocus pattern that appears to slow axial growth, though they require careful fitting and diligent cleaning routines.
Myopia-Control Spectacle Lenses
For children who aren’t ready for contact lenses or eye drops, specially designed glasses offer a middle ground. These look like ordinary lenses but contain hundreds of tiny segments or lenslets embedded across the surface. Each segment creates a small zone of defocus that signals the eye to slow its growth, while the central portion of the lens provides a clear, fully corrected image for everyday seeing.
Three main designs exist. A retrospective cohort study published in Ophthalmology Science compared all three against standard single-vision lenses and found that each design meaningfully reduced structural eye elongation. Among them, one design (known by the abbreviation HALT) showed the greatest short-term slowing of axial growth, while the others provided solid alternatives that clinicians can choose based on a child’s specific needs, lens availability, and cost.
These lenses are a practical first step for younger children or families hesitant about drops or contacts, since wearing glasses is already familiar and carries no compliance learning curve beyond keeping them on.
Monitoring Progress Over Time
Starting treatment is only the first step. The International Myopia Institute emphasizes that ongoing monitoring with both prescription checks and axial length measurements is essential. Axial length, the front-to-back measurement of the eye in millimeters, is the most reliable indicator of whether a treatment is working. A child’s prescription can fluctuate with accommodation and measurement conditions, but axial length tracks the structural change that drives long-term risk.
Regular retinal health checks are also recommended even in younger patients, because the link between eye length and potential damage to the retina is strong. This isn’t limited to childhood. Clinically, monitoring should continue into early adulthood, especially for patients with higher myopia, since some eyes keep growing into the mid-twenties.
Combining Treatments
Many eye care practitioners layer two approaches together when a single treatment isn’t producing enough slowing. A common combination pairs low-dose atropine drops with either myopia-control glasses or specialty contact lenses. Because the drops and the optical treatments appear to work through different mechanisms, their effects can complement each other. The decision to combine therapies usually depends on how fast a child’s myopia is progressing and how they respond to the first intervention over six to twelve months.
Outdoor time remains a simple, evidence-supported protective factor regardless of which clinical treatment is chosen. Children who spend at least two hours a day outside have lower rates of myopia onset. While outdoor time alone is unlikely to halt progression once myopia has started, it adds a layer of protection and costs nothing.